WO2007054303A3 - Diaryl urea for treating diabetic neuropathy - Google Patents

Diaryl urea for treating diabetic neuropathy Download PDF

Info

Publication number
WO2007054303A3
WO2007054303A3 PCT/EP2006/010747 EP2006010747W WO2007054303A3 WO 2007054303 A3 WO2007054303 A3 WO 2007054303A3 EP 2006010747 W EP2006010747 W EP 2006010747W WO 2007054303 A3 WO2007054303 A3 WO 2007054303A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic neuropathy
treating diabetic
diaryl urea
diaryl
urea
Prior art date
Application number
PCT/EP2006/010747
Other languages
French (fr)
Other versions
WO2007054303A2 (en
Inventor
Olaf Weber
Bernd Riedl
Original Assignee
Bayer Healthcare Ag
Olaf Weber
Bernd Riedl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Olaf Weber, Bernd Riedl filed Critical Bayer Healthcare Ag
Priority to CA002628881A priority Critical patent/CA2628881A1/en
Priority to JP2008539336A priority patent/JP2009514921A/en
Priority to EP06806712A priority patent/EP1948144A2/en
Publication of WO2007054303A2 publication Critical patent/WO2007054303A2/en
Publication of WO2007054303A3 publication Critical patent/WO2007054303A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical compositions for treating diabetic neuropathy comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2- carboxylic acid methylamide optionally combined with at least one additional therapeutic agent.
PCT/EP2006/010747 2005-11-10 2006-11-09 Diaryl urea for treating diabetic neuropathy WO2007054303A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002628881A CA2628881A1 (en) 2005-11-10 2006-11-09 Diaryl urea for treating diabetic neuropathy
JP2008539336A JP2009514921A (en) 2005-11-10 2006-11-09 Diarylureas for treating diabetic neuropathy
EP06806712A EP1948144A2 (en) 2005-11-10 2006-11-09 Diaryl urea for treating diabetic neuropathy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05024507.5 2005-11-10
EP05024507 2005-11-10
EP05027448 2005-12-15
EP05027448.9 2005-12-15

Publications (2)

Publication Number Publication Date
WO2007054303A2 WO2007054303A2 (en) 2007-05-18
WO2007054303A3 true WO2007054303A3 (en) 2008-03-20

Family

ID=38023616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/010747 WO2007054303A2 (en) 2005-11-10 2006-11-09 Diaryl urea for treating diabetic neuropathy

Country Status (5)

Country Link
EP (1) EP1948144A2 (en)
JP (1) JP2009514921A (en)
KR (1) KR20080074974A (en)
CA (1) CA2628881A1 (en)
WO (1) WO2007054303A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY183969A (en) * 2012-09-25 2021-03-17 Bayer Pharma AG Combination of regorafenib and acetylsalicylic acid for treating cancer
FI3630112T3 (en) 2017-06-02 2024-05-02 Bayer Healthcare Llc Combination of regorafenib and nivolumab for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AGTHONG SITHIPORN ET AL: "Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES NOV 2002, vol. 973, November 2002 (2002-11-01), pages 359 - 362, XP002465943, ISSN: 0077-8923 *

Also Published As

Publication number Publication date
WO2007054303A2 (en) 2007-05-18
JP2009514921A (en) 2009-04-09
CA2628881A1 (en) 2007-05-18
EP1948144A2 (en) 2008-07-30
KR20080074974A (en) 2008-08-13

Similar Documents

Publication Publication Date Title
TW200733961A (en) Diaryl urea for treating pulmonary hypertension
LTC1793824I2 (en) New pharmaceutical compositions comprising 4- (4- (3- (4-chloro-3-trifluoromethylphenyl) ureido) -3-fluorophenoxy) pyridine-2-carboxylic acid for the treatment of hyperproliferative disorders
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
WO2006120682A3 (en) Compositions and methods for treating hyperproliferative epidermal diseases
TW200735869A (en) Diaryl ureas for treating pulmonary hypertension
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
IL190951A0 (en) Method of acting upon organism by targeted delivery of biologicaly active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
WO2006125539A3 (en) Combination therapy comprising diaryl ureas for treating diseases
EP2033688A3 (en) Oxalic acid derivatives and their use as physiological cooling agents
WO2005086661A3 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
CL2007003265A1 (en) COMPOUNDS DERIVED FROM 1H-PIRAN [2,3-D] PIRIMIDIN-2,4,7-TRIONA; AND PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF METABOLIC SYNDROME, DYSLIPIDEMIA AND CARDIOVASCULAR DISEASES BETWEEN OTHERS.
WO2007066150A3 (en) Transdermal administration of active agents for systemic effect
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
WO2007031883A3 (en) Composition comprising at least one naphthoic acid derivative and at least one compound of polyurethane polymer type or derivatives thereof, preparation processes therefor and uses thereof
MX2007004294A (en) Pharmaceutical compositions comprising levetiracetam and process for their preparation.
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2006135480A3 (en) Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
TW200630336A (en) Novel compounds
CA2583764A1 (en) Thrombopoietin activity modulating compounds and methods
WO2006000224A3 (en) Compositions comprising strontium and vitamin d and uses thereof
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
PL1979521T3 (en) Novel method for impregnating a textile surface
WO2008087182A3 (en) Fungicidal mixtures of 1-methylpyrazole-4-ylcarboxylic acid anilides and azolopyrimidinylamines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680041808.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006806712

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3762/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2628881

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008539336

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087013801

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2006806712

Country of ref document: EP